PHASE 1-2, OPEN-LABEL, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRATHECALLY-ADMINISTERED ION337 IN PATIENTS WITH DRAVET SYNDROME

Registry ID

ION337-CS1

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

IONIS PHARMACEUTICALS INC

Last update

2026-03-04

Conditions

• DRAVET SYNDROME

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF LP352 IN THE TREATMENT OF SEIZURES IN CHILDREN AND ADULTS WITH DRAVET SYNDROME
• A 20-WEEK MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EPX-100 (CLEMIZOLE HYDROCHLORIDE) AS ADJUNCTIVE THERAPY IN CHILDREN AND ADULT PARTICIPANTS WITH DRAVET SYNDROME (ARGUS TRIAL)
• CANNABIDIOL IN CHILDREN WITH REFRACTORY EPILEPTIC ENCEPHALOPATHY: A PHASE 1 OPEN LABEL DOSE ESCALATION STUDY

View on source registry